Skip to main content
OpenTrials

Clinical trial condition

Smoking Cessation

Explore clinical trials studying Smoking Cessation. Study availability and eligibility vary by location and protocol.

1,297 public trials 113 recruiting studies
Refine in advanced search Browse all conditions

Smoking Cessation trial results

Completed

An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

NCT00143325

Conditions
Behavior, Health Behavior, Smoking Cessation
Locations
  • Pfizer Investigational Site Palo Alto, California, United States
  • Pfizer Investigational Site Santa Ana, California, United States
  • Pfizer Investigational Site Farmington, Connecticut, United States
  • Pfizer Investigational Site Lexington, Kentucky, United States
View all 22 locations
View Trial Details
Completed

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

NCT00141206

Conditions
Behavior, Health Behavior, Smoking Cessation
Locations
  • Pfizer Investigational Site Tucson, Arizona, United States
  • Pfizer Investigational Site Los Angeles, California, United States
  • Pfizer Investigational Site Newport Beach, California, United States
  • Pfizer Investigational Site Riverside, California, United States
View all 20 locations
View Trial Details
Completed

12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.

NCT00150254

Conditions
Behavior, Health Behavior, Smoking Cessation
Locations
  • Pfizer Investigational Site Los Angeles, California, United States
  • Pfizer Investigational Site San Bernardino, California, United States
  • Pfizer Investigational Site Upland, California, United States
  • Pfizer Investigational Site West Covina, California, United States
View all 13 locations
View Trial Details
Completed

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

NCT00143286

Conditions
Behavior, Health Behavior, Smoking Cessation
Locations
  • Pfizer Investigational Site Santa Ana, California, United States
  • Pfizer Investigational Site West Palm Beach, Florida, United States
  • Pfizer Investigational Site Lexington, Kentucky, United States
  • Pfizer Investigational Site Mogadore, Ohio, United States
View all 24 locations
View Trial Details
Completed

12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation

NCT00139750

Conditions
Behavior, Health Behavior, Smoking Cessation
Locations
  • Pfizer Investigational Site Noda, Chiba, Japan
  • Pfizer Investigational Site Fukuoka, Japan
  • Pfizer Investigational Site Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site Yokohama, Kanagawa, Japan
View all 15 locations
View Trial Details
Completed

12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation

NCT00150228

Conditions
Behavior, Health Behavior, Smoking Cessation
Locations
  • Pfizer Investigational Site Lexington, Kentucky, United States
  • Pfizer Investigational Site Albert Lea, Minnesota, United States
  • Pfizer Investigational Site Rochester, Minnesota, United States
  • Pfizer Investigational Site Philadelphia, Pennsylvania, United States
View Trial Details
Completed

A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

NCT00143299

Conditions
Behavior, Health Behavior, Smoking Cessation
Locations
  • Pfizer Investigational Site Denver, Colorado, United States
  • Pfizer Investigational Site Milford, Massachusetts, United States
  • Pfizer Investigational Site Albuquerque, New Mexico, United States
  • Pfizer Investigational Site Syracuse, New York, United States
View Trial Details

Related conditions